84 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. The benefits and risks of treatment … with EMPAVELI, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known
8-K
EX-1.1
gzac6qk842i f3uj
1 Nov 23
Entry into a Material Definitive Agreement
7:59am
424B5
wcvptd0qb 7yxr289w1
1 Nov 23
Prospectus supplement for primary offering
7:51am
8-K
g13uz
29 Aug 23
Cost Associated with Exit or Disposal Activities
7:05am
8-K
EX-1.1
spu4k9znr7372dmjvjxd
24 Mar 22
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8:18pm
424B5
xjnh7a5kpbgnl7icjzac
24 Mar 22
Prospectus supplement for primary offering
8:02pm